Summary of Anixa Biosciences Fireside Chat Company Overview - **Company**: Anixa Biosciences (NasdaqCM: ANIX) - **Industry**: Biotechnology - **Focus**: Development of CAR T cell therapy for ovarian cancer and a breast cancer vaccine - **Clinical Stage**: Engaged in clinical trials for cancer therapies Key Achievements in 2025 - **Phase 1 Breast Cancer Vaccine Trial**: Completed in collaboration with Cleveland Clinic and U.S. Department of Defense, with data presented in December 2025 [5][6] - **CAR T Therapy Progress**: Significant patient outcomes reported, with advancements in clinical trials and patent approvals [5][6] - **Official Naming**: CAR T therapy received official name approval from domestic and international organizations [6] Upcoming Milestones - **Transition to Phase 2 for Breast Cancer Vaccine**: Requires FDA report submission and discussions, with plans to enroll 80-100 women [7][10] - **Manufacturing Plans**: Working with manufacturers to produce larger vaccine quantities under GLP and GMP conditions [7][8] Financial Overview - **Cash Burn**: $7 million in the last fiscal year, with an expected increase to approximately $8 million for the upcoming year [11][12] - **Cash Reserves**: $15 million cash balance with no debt, providing over two years of operational runway [12][13] CAR T Therapy Developments - **Safety and Efficacy**: Phase 1 trial focused on safety, with promising early efficacy indicators; patients have outlived expected life expectancy [16][18] - **Patient Outcomes**: Some patients lived significantly longer than the median survival of 12 weeks, with one patient living 28 months [18][19] - **Regulatory Approval**: Seeking IRB approval to escalate dosages due to positive safety profile [19] Mechanisms of Action - **Unique Targeting**: CAR T therapy targets a unique protein present only on cancer cells, minimizing effects on healthy tissues [22] - **Anti-Angiogenesis Effect**: Potential destruction of tumor vasculature, enhancing treatment efficacy [23] - **Peritoneal Delivery**: Direct delivery to the peritoneal cavity improves therapy effectiveness and reduces systemic side effects [24] Lymphodepletion Strategy - **Introduction of Lymphodepletion**: Planned to enhance CAR T cell engraftment and proliferation, with careful monitoring of associated risks [31][33] - **Comparative Analysis**: Some cohorts will receive lymphodepletion while others will not, to evaluate its impact on patient outcomes [33] Expectations for 2026 - **Pivotal Year**: Anticipation of significant data from CAR T trials and breast cancer vaccine Phase 2 initiation [36][38] - **Control Arm in Phase 2**: Designed to evaluate the vaccine's efficacy against a control group [38] - **Fiscal Responsibility**: Commitment to maintaining financial prudence while advancing clinical trials [39] Conclusion - **Outlook**: 2026 is expected to be a busy and eventful year for Anixa, with critical data releases and potential partnerships on the horizon [39][40]